Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Interest & Investment Income: 2016-2025

Historic Interest & Investment Income for Iovance Biotherapeutics (IOVA) over the last 6 years, with Sep 2025 value amounting to $1.2 million.

  • Iovance Biotherapeutics' Interest & Investment Income fell 68.96% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 31.31%. This contributed to the annual value of $20.3 million for FY2024, which is 55.43% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Interest & Investment Income is $1.2 million, which was down 69.71% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Interest & Investment Income registered a high of $9.6 million during Q4 2024, and its lowest value of $1.2 million during Q3 2025.
  • For the 3-year period, Iovance Biotherapeutics' Interest & Investment Income averaged around $3.8 million, with its median value being $3.4 million (2024).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Interest & Investment Income spiked by 207.09% in 2024, and later slumped by 68.96% in 2025.
  • Iovance Biotherapeutics' Interest & Investment Income (Quarterly) stood at $3.1 million in 2023, then spiked by 207.09% to $9.6 million in 2024, then tumbled by 68.96% to $1.2 million in 2025.
  • Its Interest & Investment Income stands at $1.2 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.2 million for Q1 2025.